医学
前列腺癌
毒性
放射治疗
直肠
前列腺
泌尿生殖系统
泌尿科
外照射放疗
累积剂量
结直肠癌
内科学
癌症
外科
肿瘤科
作者
Ulrika Björeland,Kristina Notstam,Per Fransson,Karin Söderkvist,Lars Beckman,Joakim H Jonsson,Tufve Nyholm,Anders Widmark,Camilla Thellenberg Karlsson
标识
DOI:10.1186/s13014-022-02197-x
摘要
BACKGROUND: Perirectal spacers may be beneficial to reduce rectal side effects from radiotherapy (RT). Here, we present the impact of a hyaluronic acid (HA) perirectal spacer on rectal dose as well as spacer stability, long-term gastrointestinal (GI) and genitourinary (GU) toxicity and patient-reported outcome (PRO). METHODS: In this phase II study 81 patients with low- and intermediate-risk prostate cancer received transrectal injections with HA before external beam RT (78 Gy in 39 fractions). The HA spacer was evaluated with MRI four times; before (MR0) and after HA-injection (MR1), at the middle (MR2) and at the end (MR3) of RT. GI and GU toxicity was assessed by physician for up to five years according to the RTOG scale. PROs were collected using the Swedish National Prostate Cancer Registry and Prostate cancer symptom scale questionnaires. RESULTS: There was a significant reduction in rectal V70% (54.6 Gy) and V90% (70.2 Gy) between MR0 and MR1, as well as between MR0 to MR2 and MR3. From MR1 to MR2/MR3, HA thickness decreased with 28%/32% and CTV-rectum space with 19%/17% in the middle level. The cumulative late grade ≥ 2 GI toxicity at 5 years was 5% and the proportion of PRO moderate or severe overall bowel problems at 5 years follow-up was 12%. Cumulative late grade ≥ 2 GU toxicity at 5 years was 12% and moderate or severe overall urinary problems at 5 years were 10%. CONCLUSION: We show that the HA spacer reduced rectal dose and long-term toxicity.
科研通智能强力驱动
Strongly Powered by AbleSci AI